認知症(Dementia):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Dementia - Pipeline Review, H2 2014
◆商品コード:GMDHC5794IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:110
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における認知症(Dementia)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・認知症(Dementia)の概要
・認知症(Dementia)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・認知症(Dementia)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・認知症(Dementia)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・認知症(Dementia)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Dementia – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Dementia – Pipeline Review, H2 2014’, provides an overview of the Dementia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dementia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dementia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Dementia Overview 10
Therapeutics Development 11
Pipeline Products for Dementia – Overview 11
Pipeline Products for Dementia – Comparative Analysis 12
Dementia – Therapeutics under Development by Companies 13
Dementia – Therapeutics under Investigation by Universities/Institutes 15
Dementia – Pipeline Products Glance 17
Clinical Stage Products 17
Early Stage Products 18
Dementia – Products under Development by Companies 19
Dementia – Products under Investigation by Universities/Institutes 21
Dementia – Companies Involved in Therapeutics Development 22
Alector LLC 22
Biotie Therapies Corp. 23
Bristol-Myers Squibb Company 24
Chase Pharmaceuticals Corporation 25
Chronos Therapeutics Limited 26
Echo Pharmaceuticals B.V. 27
FORUM Pharmaceuticals Inc. 28
Hyundai Pharmaceutical Co., Ltd. 29
Ildong Pharmaceutical Co., Ltd. 30
ImStar Therapeutics Inc. 31
Integrative Research Laboratories Sweden AB 32
Intellect Neurosciences, Inc. 33
Intra-Cellular Therapies, Inc. 34
Oryzon Genomics S.A. 35
Pacific Northwest Biotechnology, LLC 36
SK Chemicals Co., Ltd. 37
Stelic Institute & Co. 38
Summit Corporation plc 39
Sylentis S.A. 40
Tautatis Incorporated 41
WhanIn Pharmaceutical Co., Ltd. 42
Dementia – Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
Antibodies for Dementia and Alzheimer’s Disease – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Antisense Oligonucleotide to Inhibit microRNA for Neurology – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
choline alfoscerate SR – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CPC-252 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
dronabinol – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Drugs for Dementia – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Drugs to Agonize c-MET for Dementia – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
FRM-0334 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
GIBH-130 – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
gugulipid – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
IPN-007 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
IRL-752 – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ITI-007 – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
KR-12 – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Monoclonal Antibodies to Inhibit Tau for CNS Disorders – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
NAT – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
NNC-269100 – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
OG-635 – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Peptide to Inhibit BACE for Cerebropathy and Dementia – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RDC-5 – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
RNAi Oligonucleotide for Cerebral Ischemia and Dementia – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SID-111 – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecule to Activate LPL for CNS and Metabolic Disorders – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecule to Inhibit Glycogene 5 for Dementia – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecule to Inhibit O-linked N-acetylglucosaminidase for Neurodegenerative Diseases – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecules for Ophthalmology and CNS Disorders – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Inhibit LSD-1 And MAO-B for Neurodegenerative Diseases – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer’s Disease – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
SYN-120 – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Synthetic Peptides for Neurological Disorders – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
TauC3 Monoclonal Antibody – Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
TPI-287 – Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
TTT-3002 – Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
WIB-1001C – Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Dementia – Recent Pipeline Updates 92
Dementia – Dormant Projects 99
Dementia – Discontinued Products 101
Dementia – Product Development Milestones 102
Featured News & Press Releases 102
Oct 28, 2014: FORUM Pharmaceuticals Presents FRM-0334 Studies at 9th International Conference on Frontotemporal Dementias 102
Sep 19, 2014: Aricept Approved In Japan As Treatment For Dementia With Lewy Bodies 103
Oct 31, 2013: Eisai Submits Application to Expand Indication of Anti-alzheimer’s Agent Aricept As Treatment for Dementia with Lewy Bodies in Japan 104
Aug 02, 2012: Namisol phase II study commence in pain in dementia 105
Feb 23, 2011: Intellectual Property High Court of Japan Rules to Maintain Aricept Patent Term Extension in Relation to Severe Alzheimer’s Dementia 105
Jul 24, 2010: Eisai Announces U.S. FDA Approval for New Higher Dose Aricept 23mg Tablet for the Treatment of Moderate-to-severe Alzheimer’s Disease 105
Nov 24, 2009: FDA Accepts Once Daily 23 mg Aricept Extended Release NDA for Review 106
Sep 25, 2009: Pfizer and Eisai Continue Aricept Collaboration 106
Jul 22, 2009: Eisai Receives Approval for a New Oral Jelly Formulation of Aricept for the Treatment of Alzheimer’s Disease in Japan 107
Oct 16, 2006: U.S. Food and Drug Administration Approves ARICEPT for Treatment of Severe Alzheimer’s Disease 107
Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 110
Disclaimer 110

[List of Tables]
Number of Products under Development for Dementia, H2 2014 11
Number of Products under Development for Dementia - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Development by Companies, H2 2014 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2014 21
Dementia - Pipeline by Alector LLC, H2 2014 22
Dementia - Pipeline by Biotie Therapies Corp., H2 2014 23
Dementia - Pipeline by Bristol-Myers Squibb Company, H2 2014 24
Dementia - Pipeline by Chase Pharmaceuticals Corporation, H2 2014 25
Dementia - Pipeline by Chronos Therapeutics Limited, H2 2014 26
Dementia - Pipeline by Echo Pharmaceuticals B.V., H2 2014 27
Dementia - Pipeline by FORUM Pharmaceuticals Inc., H2 2014 28
Dementia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2014 29
Dementia - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2014 30
Dementia - Pipeline by ImStar Therapeutics Inc., H2 2014 31
Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2014 32
Dementia - Pipeline by Intellect Neurosciences, Inc., H2 2014 33
Dementia - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 34
Dementia - Pipeline by Oryzon Genomics S.A., H2 2014 35
Dementia - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2014 36
Dementia - Pipeline by SK Chemicals Co., Ltd., H2 2014 37
Dementia - Pipeline by Stelic Institute & Co., H2 2014 38
Dementia - Pipeline by Summit Corporation plc, H2 2014 39
Dementia - Pipeline by Sylentis S.A., H2 2014 40
Dementia - Pipeline by Tautatis Incorporated, H2 2014 41
Dementia - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2014 42
Assessment by Monotherapy Products, H2 2014 43
Number of Products by Stage and Target, H2 2014 45
Number of Products by Stage and Mechanism of Action, H2 2014 47
Number of Products by Stage and Route of Administration, H2 2014 49
Number of Products by Stage and Molecule Type, H2 2014 51
Dementia Therapeutics - Recent Pipeline Updates, H2 2014 92
Dementia - Dormant Projects, H2 2014 99
Dementia - Dormant Projects (Contd..1), H2 2014 100
Dementia - Discontinued Products, H2 2014 101

[List of Figures]
Number of Products under Development for Dementia, H2 2014 11
Number of Products under Development for Dementia - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Products, H2 2014 18
Assessment by Monotherapy Products, H2 2014 43
Number of Products by Top 10 Targets, H2 2014 44
Number of Products by Stage and Top 10 Targets, H2 2014 44
Number of Products by Top 10 Mechanism of Actions, H2 2014 46
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 46
Number of Products by Top 10 Routes of Administration, H2 2014 48
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 49
Number of Products by Top 10 Molecule Types, H2 2014 50
Number of Products by Stage and Top 10 Molecule Types, H2 2014 51

【掲載企業】

Alector LLC
Biotie Therapies Corp.
Bristol-Myers Squibb Company
Chase Pharmaceuticals Corporation
Chronos Therapeutics Limited
Echo Pharmaceuticals B.V.
FORUM Pharmaceuticals Inc.
Hyundai Pharmaceutical Co., Ltd.
Ildong Pharmaceutical Co., Ltd.
ImStar Therapeutics Inc.
Integrative Research Laboratories Sweden AB
Intellect Neurosciences, Inc.
Intra-Cellular Therapies, Inc.
Oryzon Genomics S.A.
Pacific Northwest Biotechnology, LLC
SK Chemicals Co., Ltd.
Stelic Institute & Co.
Summit Corporation plc
Sylentis S.A.
Tautatis Incorporated
WhanIn Pharmaceutical Co., Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[認知症(Dementia):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆